In the process of conquering difficult drug targets, we cooperate with research institutions, biotechnology companies, and pharmaceutical companies around the world at all stages of drug discovery, clinical research, and commercialization. We look for the best therapies and bring products to the global market through external licensing, product introduction, and co-development.
Global commercialization and development collaboration
We have signed a global, strategic collaboration agreement to develop and commercialise SHP2 inhibitors with AbbVie on June 1, 2020.
Click here to know more about our partnership.
Providing new treatment options for patients
In October, 2022, we have entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor Glecirasib (JAB-21822) and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux® (cetuximab).
Click here to know more about our partnership.
In March, 2023, we have entered into a clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combinationof Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
Click here to know more about our partnership.
Using the latest research to bring hope to patients
Click here to know more about our partnership.
Helping with early drug discovery
Collaborations in drug R&D
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP B 17065868-1 
京公网安备 11030102011242号